4-Star Stocks Poised to Pop: SciClone Pharmaceuticals

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company SciClone Pharmaceuticals (Nasdaq: SCLN  ) has earned a respected four-star ranking.

With that in mind, let's take a closer look at SciClone's business and see what CAPS investors are saying about the stock right now.

SciClone facts

Headquarters (founded) Foster City, Calif. (1989)
Market Cap $326.5 million
Industry Pharmaceuticals
Trailing-12-Month Revenue $158.3 million
Management CEO Dr. Friedhelm Blobel (since 2006)
CFO Gary Titus (since 2008)
Return on Equity (average, past 3 years) 23.4%
Cash/Debt $81.6 million / $2.5 million
Competitors Biostar Pharmaceuticals
Gilead Sciences
Roche Holding

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 93% of the 165 members who have rated SciClone believe the stock will outperform the S&P 500 going forward.  

A few months ago, one of those Fools, All-Star zzlangerhans, tapped SciClone as a relatively solid biotech selection:

What I do like about SciClone is that they've been solidly profitable for the last three quarters and they're using profits to build a stronger cash position. Since dilution seems to be a much more prevalent source of pipeline funding in the baby biotech sector, profitability always gets my attention. The remnants of SciClone's pipeline seem to have died out so a new acquisition is a substantial possibility.

If you want market-thumping returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite a strong four-star rating, SciClone may not be your top choice.

We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of Gilead. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.


Read/Post Comments (0) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2040044, ~/Articles/ArticleHandler.aspx, 10/20/2014 9:26:36 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement